Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Lakshminarayanan Nandagopal
Assistant Professor
Close
E-mail
lnandago@uab.edu
Links
ResearchGate
LinkedIn
Google Scholar
Visualizations
Co-author Network
Map of Science
Co-investigator Network
Lakshminarayanan Nandagopal
Assistant Professor
Positions
Associate Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
Associate Scientist
,
Experimental Therapeutics
,
O'Neal Comprehensive Cancer Center
Associate Scientist (C)
,
Center for Clinical and Translational Science (CCTS)
,
General Clinical Research Center
Assistant Professor (P)
,
Medicine - Hematology & Oncology
,
Department of Medicine
Publications
Research
Contact
Publications
Selected Publications
Academic Article
Filter
Year
Title
Altmetric
2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race
2022
2022
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
.
Frontiers in Oncology
. 12.
2022
2022
Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 20:866-878.
2022
2022
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
2022
2022
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 20:71-90.
2022
2022
Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with Cancer
2022
2021
Association between chronologic age and geriatric assessment⇓identified impairments: Findings from the CARE registry
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 19:922-927.
2021
2020
Obesity diminishes response to PD-1-based immunotherapies in renal cancer
.
Journal for ImmunoTherapy of Cancer
. 8.
2020
2020
First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern Oncotherapeutics
.
Scientific Reports
. 10.
2020
2020
Kidney cancer, version 1.2021: Featured updates to the nccn guidelines
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 18:1160-1170.
2020
2020
Patient-reported cognitive complaints in older adults with gastrointestinal malignancies at diagnosis– Results from the Cancer & Aging Resilience Evaluation (CARE) study
.
Journal of Geriatric Oncology
. 11:982-988.
2020
2020
Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE)
.
Journal of Geriatric Oncology
. 11:270-273.
2020
2020
Bladder cancer, version 3.2020
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 18:329-354.
2020
2019
Investigational MET inhibitors to treat Renal cell carcinoma
.
Expert Opinion on Investigational Drugs
. 28:851-860.
2019
2019
Correction to: Immunotherapy Advances in Urothelial Carcinoma (Current Treatment Options in Oncology, (2018), 19, 12, (79), 10.1007/s11864-018-0598-x)
.
Current Treatment Options in Oncology
. 20.
2019
2019
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
.
Cancer
. 125:1459-1469.
2019
2019
Featured updates to the NCCN guidelines
.
Journal of the National Comprehensive Cancer Network : JNCCN
. 17:1278-1285.
2019
2018
Correlation between Dt/V derived from ionic dialysance and blood-driven Kt/V of urea in African-American hemodialysis patients, based on body weight and ultrafiltration volume
.
Clinical Kidney Journal
. 11:734-741.
2018
2018
Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma
.
Current Treatment Options in Oncology
. 19.
2018
2017
Timing of androgen-deprivation therapy in prostate cancer
2017
2017
Treatment approaches of hard-to-treat non-Hodgkin lymphomas
.
Expert Review of Hematology
. 10:259-273.
2017
2016
Bronchoscopy can be done safely in patients with thrombocytopenia
.
Transfusion
. 56:344-348.
2016
2016
Circulating biomarkers in bladder cancer
.
Bladder cancer
. 2:369-379.
2016
2014
Ectopic ACTH and cisplatin toxicity-a diagnostic dilemma
.
American Journal of Therapeutics
. 21:e154-e156.
2014
2013
A rare cause of dysphagia in a HIV patient - esophageal pseudodiverticulosis
.
Acta Gastro-Enterologica Belgica
. 76:340-341.
2013
2013
Sterile peritonitis because of splenic infarction in a patient on peritoneal dialysis: An unusual presentation
.
Advances in peritoneal dialysis. Conference on Peritoneal Dialysis
. 33:339-340.
2013
Research
Research Overview
Dr. Nandagopal’s primary clinic interest is interested in genitourinary (GU) malignancies. His research interests are in developing clinical trials for GU malignancies, and development of correlative and prognostic biomarkers.
Principal Investigator On
Alliance for Clinical Trials in Oncology Payment Agreement
awarded by
MAYO CLINIC
Private Grant
awarded by
CALITHERA BIOSCIENCES INC
Private Grant
awarded by
ASTRAZENECA PHARMACEUTICALS LP
Private Grant
awarded by
JOUNCE THERAPEUTICS, INC
Private Grant
awarded by
MEDIVATION, INC
Private Grant
awarded by
I-MAB BIOPHARMA US LIMITED
Private Grant
awarded by
MERCK SHARP & DOHME CORP
Private Grant
awarded by
SEATTLE GENETICS, INC.
Private Grant
awarded by
AMGEN, INC.^
Private Grant
awarded by
Pfizer Pharmaceuticals
Private Grant
awarded by
ASTRAZENECA PHARMACEUTICALS LP
UAB 1395 - Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
awarded by
KARMANOS CANCER CENTER
Investigator On
Alliance for Clinical Trials in Oncology Payment Agreement
awarded by
MAYO CLINIC
Comprehensive Cancer Center Core Support Grant
awarded by
National Cancer Institute/NIH/DHHS
Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)
awarded by
National Cancer Institute/NIH/DHHS
ECOG-ACRIN Purchase Service Agreement
awarded by
Eastern Cooperative Oncology Group
ECOG-ACRIN Purchase Service Agreement
awarded by
Eastern Cooperative Oncology Group
Private Grant
awarded by
CLOVIS ONCOLOGY
Private Grant
awarded by
CLOVIS ONCOLOGY
Private Grant
awarded by
ASTRAZENECA AB
Private Grant
awarded by
ABBVIE INC
Private Grant
awarded by
ASTRAZENECA PHARMACEUTICALS LP
Private Grant
awarded by
PUMA BIOTECHNOLOGY, INC.
Private Grant
awarded by
CALITHERA BIOSCIENCES INC
Private Grant
awarded by
ADURO BIOTECH, INC.
Private Grant
awarded by
ELI LILLY AND COMPANY
Private Grant
awarded by
ARCUS BIOSCIENCES INC
Private Grant
awarded by
ELI LILLY AND COMPANY
Private Grant
awarded by
SEATTLE GENETICS, INC.
Private Grant
awarded by
HOOKIPA BIOTECH
Private Grant
awarded by
MERCK SHARP & DOHME CORP
Private Grant
awarded by
QED THERAPEUTICS INC
Private Grant
awarded by
BLUE EARTH DIAGNONSTICS LTD ^
Private Grant
awarded by
TAKEDA PHARMACEUTICALS COMPANY LTD
Private Grant
awarded by
MERCK SHARP & DOHME CORP
Private Grant
awarded by
ELEVATION ONCOLOGY INC.
Private Grant
awarded by
MERCK SHARP & DOHME CORP
Private Grant
awarded by
IMMUNOMEDICS, INC.
Private Grant
awarded by
EMD SERONO
Private Grant
awarded by
STRATA ONCOLOGY
Private Grant
awarded by
CHECKMATE PHARMACEUTICALS INC
Private Grant
awarded by
IMMUTEP LTD
Private Grant
awarded by
STRATA ONCOLOGY
Private Grant
awarded by
AVEO PHARMACEUTICALS, INC
Private Grant
awarded by
CHECKMATE PHARMACEUTICALS INC
Private Grant
awarded by
I-MAB BIOPHARMA US LIMITED
UAB 1984: Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Ipilimumab and/or Nivolumab
awarded by
CLEVELAND CLINIC FOUNDATION
Contact
Full Name
Lakshminarayanan
Nandagopal